Drug Profile
Research programme: antioxidants - Activus Pharma
Alternative Names: TA-264; TA-381Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Activus Pharma
- Developer Nxera Pharma
- Class Quinolones
- Mechanism of Action Antifibrinolytic agents; Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Peripheral vascular disorders; Stroke